Yes, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) can occur in the same person, and their symptoms overlap. But current research does not show that MCAS causes POTS, that POTS causes MCAS, or that MCAS is unusually common among people with POTS.
Symptom overlap alone can’t diagnose either condition, so each needs to be assessed using its own criteria. Below, we look at what the evidence shows, how POTS and MCAS are diagnosed, and what this means for treatment and diet.
Are MCAS and POTS actually connected?
The evidence looks contradictory because the studies measured different things in different patients. Following it in order shows why.
In 2005, a small Vanderbilt study described referred POTS patients with flushing, abnormal urine methylhistamine and hyperadrenergic postural responses. That was a selected subgroup, so it generated a hypothesis and didn’t establish how common the overlap is.
A 2021 study of 69 POTS patients found that 44 had extra symptoms not typical of POTS, such as migraine, allergic complaints, rash or gut symptoms. Of those 44, 29 had at least one elevated mast-cell-associated marker. That does not mean 42% of all people with POTS have MCAS. An abnormal marker isn’t a diagnosis, and a later paper noted that under strict consensus-1 criteria only 2 of those 69 would have been labeled MCAS.
That later paper, a 2025 retrospective review of 100 young POTS patients, shows how much the definition matters. Reported MCAS frequency ran from 2% under strict criteria to 87% under broad clinical criteria, with a conservative consensus-2 definition in between. Those figures show definition dependence. They don’t give a prevalence.
A 2025 systematic review then looked for studies meeting prespecified strict diagnostic criteria for both conditions. It found none that confirmed a relationship between mast cell activation disorders and POTS or Ehlers-Danlos syndrome, and it called for more rigorous studies.
A 2026 paper from Mayo Clinic is titled as finding a lack of evidence for increased MCAS prevalence in POTS and in hypermobile Ehlers-Danlos syndrome. This article relies on that title alone and can’t describe its methods or numbers.
Three things explain most of the apparent contradiction.
- First, the studies used different definitions of MCAS, and the number of people who qualify changes enormously with the definition.
- Second, several of the studies enrolled patients referred to specialist clinics, who are more likely to have complex symptoms than people with POTS in general.
- Third, at least one was a retrospective chart review, a design that can show a pattern but can’t show cause and effect.
For readers, the practical takeaway is modest. The overlap is real in some people, but no single study has pinned down how often it happens or whether one condition drives the other.
Why the symptoms can look so similar
Both conditions can affect the heart rate, blood pressure, gut and head, so many everyday symptoms fit either one. Palpitations, lightheadedness, fatigue, headache and nausea can appear in POTS and in MCAS.
Some clues lean toward mast cells: flushing, hives or itching, swelling, wheeze and allergic-type episodes that involve several body systems. The table shows where the two overlap and where they differ.
| Feature | POTS | MCAS | Overlap note |
|---|---|---|---|
| Defining feature | Chronic orthostatic intolerance with a sustained heart-rate rise on standing or tilt | Recurrent systemic mast-cell-mediator episodes with objective biochemical evidence and treatment response under consensus criteria | Neither is defined by one symptom |
| Typical symptoms | Fast heart rate on standing, lightheadedness, fatigue | Flushing, hives or itching, swelling, wheeze, diarrhea, low blood pressure during episodes | Palpitations, lightheadedness, headache and nausea can occur in both |
| Clues pointing to mast cells | Not typical of POTS alone | Allergic-type, multi-system episodes | These clues have other possible causes too |
| Timing | Tied to upright posture | Episodic, not necessarily linked to posture | Some people have both patterns |
| Confirmation | Standing or tilt testing, with other causes considered | Objective biochemical evidence plus response to mediator-targeted treatment | A result for one does not confirm the other |
When might mast-cell activation be worth evaluating in someone with POTS?
It can be worth raising with a clinician when POTS comes with recurring episodes that look allergic or multi-system rather than driven by posture. This is pattern recognition, not diagnosis.
Patterns that may prompt a closer look include:
- recurrent flushing
- hives or itching
- swelling or wheeze
- allergic-type episodes
- recurrent diarrhea or nausea as part of multi-system episodes
- symptoms that aren’t limited to being upright
Each of these still has multiple possible causes, and none confirms MCAS.
How are POTS and MCAS diagnosed separately?
POTS is diagnosed from orthostatic symptoms plus a heart-rate rise of at least 30 beats per minute in adults, or 40 in adolescents, during 10 minutes of standing or tilt testing. The current international consensus also requires that no better explanation, such as major orthostatic hypotension, accounts for the picture.
MCAS has three parts under the commonly used consensus framework: recurrent systemic episodes involving more than one organ system, objective biochemical evidence of mast-cell activation, and a meaningful response to treatment aimed at mast-cell mediators. The full testing process has its own page, MCAS testing.
Having POTS does not satisfy MCAS criteria, and having MCAS does not establish POTS.
Is hyperadrenergic POTS the same as POTS with MCAS?
No. The early mast-cell and POTS work described hyperadrenergic findings in a selected subgroup, which is where the confusion started.
Hyperadrenergic POTS, a form with excessive sympathetic nervous system activation, can exist without MCAS. It isn’t the mast-cell subtype of POTS. The details are in the hyperadrenergic POTS guide.
What about EDS, hEDS, POTS and MCAS together?
You may see the three conditions grouped as a “triad” or “trifecta,” usually with Ehlers-Danlos syndrome (EDS) or its hypermobile form (hEDS). That’s popular shorthand, not an established medical entity.
The 2025 systematic review didn’t confirm a clear relationship under strict criteria. Definition-sensitive studies show why reported overlap varies so much between sources. Many people have more than one of these conditions, but that doesn’t prove they form a single syndrome.
Does treating MCAS improve POTS?
Not established. Confirmed MCAS should be treated for its own symptoms, and POTS needs its own management.
Mast-cell-directed treatment may improve mast-cell symptoms in some patients. There isn’t enough controlled evidence that it treats orthostatic tachycardia itself, and a review of mast-cell treatment in POTS found the POTS-specific evidence limited. Mast-cell drugs shouldn’t be presented as an established POTS therapy.
Response to an antihistamine also doesn’t diagnose MCAS, because treatment response alone is not specific enough to establish the diagnosis. This article gives no medication dosing, since that belongs with your treating clinician.
Is there a special diet for POTS and MCAS?
No validated combined POTS-MCAS diet exists. A broad low-histamine diet isn’t a treatment for POTS.
When food-associated mast-cell symptoms are part of a clinician-led evaluation, individualized trigger work may be relevant. Avoid escalating restriction, though, because a shrinking food list carries its own nutritional costs. For how MCAS differs from histamine intolerance, see MCAS vs histamine intolerance.
When do symptoms need urgent assessment?
Seek emergency care for any of these:
- difficulty breathing, or swelling of the throat or tongue
- a rapidly progressing allergic-type reaction affecting several body systems
- severe fainting
- severe chest pain
- a new neurological deficit
Don’t delay emergency treatment to obtain a diagnostic sample. If you have a prescribed emergency plan, follow it.
Bottom line
POTS and MCAS can coexist, but the evidence doesn’t show that either causes the other, and no reliable single percentage describes how often MCAS occurs in POTS. In one selected 2025 cohort, classification ranged from 2% to 87% depending on the MCAS criteria used; that spread demonstrates definition dependence, not population prevalence.
Each diagnosis stands on its own criteria. If you have POTS and episodes that look allergic or multi-system, that is a reason to ask about mast-cell evaluation, not a reason to assume MCAS.
References
- Sivakoti K, Cortez M, Fedorowski A, et al. Postural Orthostatic Tachycardia Syndrome (POTS) and Dysautonomia: International Multidisciplinary Expert Consensus. Am J Med. 2026. doi:10.1016/j.amjmed.2026.08.012.
- Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-225. doi:10.1159/000328760.
- Shibao C, Arzubiaga C, Roberts LJ 2nd, Raj S, Black B, Harris P, Biaggioni I. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385-390. doi:10.1161/01.HYP.0000158259.68614.40.
- Kohno R, Cannom DS, Olshansky B, et al. Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association. J Am Heart Assoc. 2021;10(17):e021002. doi:10.1161/JAHA.121.021002.
- Yao L, Subramaniam K, Raja KM, et al. Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients; prevalence, overlap and response to therapy depends on the definition. Front Neurol. 2025;16:1513199. doi:10.3389/fneur.2025.1513199.
- Farley M, Estrada-Mendizabal RJ, Gansert EA, et al. Prevalence of mast cell activation disorders and hereditary alpha tryptasemia among patients with postural orthostatic tachycardia syndrome and Ehlers-Danlos syndrome: A systematic review. Ann Allergy Asthma Immunol. 2025;135(1):97-102. doi:10.1016/j.anai.2025.03.022.
- Valdez JA, Gansert E, Bhuiyan FJ, et al. Lack of evidence for increased mast cell activation syndrome prevalence in postural orthostatic tachycardia syndrome and/or hypermobile Ehlers-Danlos syndrome. J Allergy Clin Immunol Pract. 2026. doi:10.1016/j.jaip.2026.08.005.
- Afrin LB, Blitshteyn S, Bluestein LS, et al. Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years. Diagnosis (Berl). 2026. doi:10.1515/dx-2026-0016.
- Doherty TA, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83-88. doi:10.1016/j.autneu.2018.05.001.
